EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

RAS–Pathway Mutation Profiles and Clinical Outcomes Among Patients With Colorectal Cancer

Elham Kazemian iD, Louisa Liu, Barliz Waissengrin iD, Marco Matejcic, Daniel Sobieski, Ya-Yu Tsai iD, Nicole C Loroña iD, Nathalie T Nguyen iD, José A Oliveras Torres iD, W Douglas Cress iD, Edna R Gordián, Erin M Siegel und 3 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.72411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Elham Kazemian und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Cancer, Cedars-Sinai Health Sciences University, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Mutation, Proto-Oncogene Proteins p21(ras), ras Proteins. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Somatic alterations in the RAS–RAF–MAPK and PI3K pathways are key in colorectal cancer (CRC), yet their distribution, co‐occurrence patterns, and clinical significance remain incompletely defined. We characterized RAS/MAPK‐ and PI3K‐pathway alterations in a large cohort and assessed their prognostic implications.

Methods

We analyzed whole‐exome sequencing data from 1243 paired samples from patients with CRC. Somatic variants in KRAS , NRAS , HRAS , BRAF , and PIK3CA were analyzed to quantify frequencies, codon‐level distributions, and co‐occurrence patterns. Descriptive somatic mutation status and demographic and clinical characteristics were evaluated using chi‐square or Fisher exact tests, and associations with overall survival (OS) were evaluated using multivariable Cox proportional hazards models.

Results

Any RAS‐family mutation was detected in 507 tumors (40.8%); KRAS , NRAS , and HRAS mutations occurred in 35.3%, 5.4%, and 0.6%, respectively. BRAF V600E was detected in 85 tumors (6.8%), PIK3CA in 221 (17.8%), and KRAS G12C in 38 (3.1%). KRAS codon 12 was the dominant RAS hotspot. KRAS‐PIK3CA co‐mutations occurred in 126 tumors (10.1% overall; 28.7% of KRAS ‐mutant tumors), whereas KRAS‐BRAF and KRAS‐NRAS co‐mutations were uncommon, consistent with MAPK pathway mutual exclusivity. RAS‐mutant tumors were enriched in right‐sided and microsatellite‐stable disease ( p < 0.001 for both). KRAS, BRAF V600E , and PIK3CA mutation frequencies were higher in right‐sided than left‐sided tumors. In unadjusted analyses, Hispanic patients had lower KRAS , BRAF V600E , and PIK3CA mutation frequencies than non‐Hispanic patients. After adjustment for age, sex, tumor location, and MSI status, the associations with KRAS and PIK3CA were attenuated, whereas the lower frequency of BRAF V600E among Hispanic patients persisted ( p < 0.01). Mutation status was not significantly associated with 5‐year overall survival.

Conclusions

RAS/MAPK and PI3K pathway alterations in CRC varied primarily by tumor subtype and molecular context, with clinically relevant co‐mutation patterns and a targetable KRAS G12C subset. These findings may support future clinical trials targeting the BRAF–RAS axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsMutationProto-Oncogene Proteins p21(ras)ras ProteinsHumansFemaleMaleAgedPrognosisMiddle AgedProto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesSignal TransductionAged, 80 and overExome SequencingAdult

Stichwörter der Autor:innen

BRAFPIK3CARAS mutationscolorectal cancersurvival

Substanzen

Proto-Oncogene Proteins B-rafPIK3CA protein, humanClass I Phosphatidylinositol 3-KinasesBRAF protein, humanProto-Oncogene Proteins p21(ras)ras ProteinsKRAS protein, human

Autor:innen und Institutionen

  • Cedars-Sinai Cancer, Cedars-Sinai Health Sciences University, Los Angeles, California, USA.
  • Department of Medicine, Cedars-Sinai Health Sciences University, Los Angeles, California, USA.
  • Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, California, USA.
  • Department of Genomic Sciences and Systems Biology, Cleveland Clinic Research, Cleveland, Ohio, USA.
  • Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Department of Basic Sciences, Ponce Research Institute, Ponce Health Sciences University, Ponce, Puerto Rico.

ORCID-Profile: Elham Kazemian, Barliz Waissengrin, Ya-Yu Tsai, Nicole C Loroña, Nathalie T Nguyen, José A Oliveras Torres, W Douglas Cress, Jamie K Teer, Stephanie L Schmit, Jane C Figueiredo

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Kazemian, E., Liu, L., Waissengrin, B., Matejcic, M., Sobieski, D., Tsai, Y. Y., Loroña, N. C., Nguyen, N. T., Oliveras Torres, J. A., Cress, W. D., Gordián, E. R., Siegel, E. M., Teer, J. K., Schmit, S. L., & Figueiredo, J. C. (2026). RAS–Pathway Mutation Profiles and Clinical Outcomes Among Patients With Colorectal Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.72411

Vancouver

Kazemian E, Liu L, Waissengrin B, Matejcic M, Sobieski D, Tsai YY, et al. RAS–Pathway Mutation Profiles and Clinical Outcomes Among Patients With Colorectal Cancer. Cancer Medicine. 2026. doi:10.1002/cam4.72411

BibTeX
@article{Kazemian2026,
  author = {Kazemian, Elham and Liu, Louisa and Waissengrin, Barliz and Matejcic, Marco and Sobieski, Daniel and Tsai, Ya-Yu and Loroña, Nicole C and Nguyen, Nathalie T and Oliveras Torres, José A and Cress, W Douglas and Gordián, Edna R and Siegel, Erin M and Teer, Jamie K and Schmit, Stephanie L and Figueiredo, Jane C},
  title = {RAS–Pathway Mutation Profiles and Clinical Outcomes Among Patients With Colorectal Cancer},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72411}
}
Kostenlos starten →